Cargando…
Prospective Case–Control Study of Serum Müllerian Inhibiting Substance and Breast Cancer Risk
BACKGROUND: Müllerian inhibiting substance (MIS) is a member of the transforming growth factor β family of growth and differentiation factors that inhibits elongation and branching of mammary ducts and has been shown to inhibit mammary tumor growth in vitro and in animal models. The objective of thi...
Autores principales: | Dorgan, Joanne F., Stanczyk, Frank Z., Egleston, Brian L., Kahle, Lisa L., Shaw, Christiana M., Spittle, Cynthia S., Godwin, Andrew K., Brinton, Louise A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773186/ https://www.ncbi.nlm.nih.gov/pubmed/19820206 http://dx.doi.org/10.1093/jnci/djp331 |
Ejemplares similares
-
Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk
por: Dorgan, Joanne F, et al.
Publicado: (2010) -
Anti-Mullerian hormone and endometrial cancer: a multi-cohort study
por: Fortner, Renée T, et al.
Publicado: (2017) -
Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study
por: Falk, Roni T, et al.
Publicado: (2013) -
Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone
por: Ferguson, Jackie MC, et al.
Publicado: (2018) -
Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors
por: Kim, Jang Heub, et al.
Publicado: (2014)